Biomarcadores para la evaluación de riesgo en la salud humana

  • Sandra S. Arango V.
Palabras clave: biomarcadores, toxicologia, salud ocupacional, carcinogénesis

Resumen

En el campo de la salud humana, el desarrollo, validación y uso de biomarcadores como herramientas de información para la evaluación de factores de riesgos asociados a la exposición a agentes ambientales, se incrementa cada día por la necesidad de conocer acerca de los efectos adversos generados por los diferentes entornos laborales y estilos de vida. Un biomarcador es un evento que se produce en un sistema biológico y se interpreta como indicador del estado de salud, de la esperanza de vida o del riesgo de enfermedad. Suelen clasificarse en biomarcadores de: exposición, efecto y de susceptibilidad. En esta revisión se plantea su importancia en la compresión de diferentes aspectos de las enfermedades como: diagnóstico, tratamiento, prevención, progresión de la enfermedad, respuestas a la terapia, así como su aplicación en la evaluación experimental toxicológica para el desarrollo de medicamentos o pesticidas. Además de su contribución en el desarrollo de diferentes campos de estudio como: la toxicología, salud ocupacional y la carcinogénesis

|Resumen
= 220 veces | PDF
= 79 veces|

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Sandra S. Arango V.
Correo opcional: sandraarango@itm.edu.co

Citas

(1). Ilizaliturri C, González D, Pelallo N, Domínguez G, Mejía J, Torres A, et al. Revisión de las metodologías sobre evaluación de riesgos en salud para el estudio de comunidades vulnerables en América Latina. Interciencia. 2009; 34(10): 710-717.

(2). Lock EA, Bonventre JV. Biomarkers in translation; past, present and future. Toxicology 2008; 245(3): 163-166.

(3). Llynin A, Belkowski S, Plata C. Biomarkers discovery and vali-dation: technologies and integrative approaches. trends in Biote-chnology. 2004; 8(4): 411-416

(4). Mayeux R. Biomarkers: potential uses and limitations. The jour-nal of the American Society for Experimental NeuroTherapeutics. 2004; 2(1): 182-188

(5). Schulte PA. The contributions of genetic and genomic to occupa-tional safety and health. Occup. Environ. Med. 2007; 64(1): 717-718.

(6). Poste G. Bring on the biomarkers. Nature. 2011; 469(1): 156-157

(7). Albertini RJ. Biomarker responses in human populations: towards a worldwide map. Mutat. Res. 1999; 428(1-2): 217-226.

(8). Vainio H. Review: Use of biomarkers in risk assessment. Int J Hyg Environ Health. 2001; 204(2-3): 91-102.

(9). Van den Brand P, Voorrips L, Hertz I, Shuker D, Boeing H, Spei-jers G, et al. The contribution of epidemiology. Food Chem. Toxi-col. 2002; 40(1): 387-424.

(10). Schulte PA, Hauser JE. The use of biomarkers in occupational health research, practice, and policy. Toxicology Letters. 2011 Mar.

(11). Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Dow-ning GJ, Hoth DF, et al. Biomarkers and surrogate endopoints: preferred definitions and conceptual framework. Clin. Pharmacol. Therap. 2000; 69(1): 89-95.

(12). Owen R, Depledge M, Hagger J, Jones M, Galloway T. Biomar-kers and environmental risk assessment: guiding principles from the human health field. Marine Pollution Bulletin. 2008; 56(1): 613-619.

(13). Tambor V, Fucíková A, Lenco J, Kacerovský M, Rehácek V, Stu-lík J, et al. Application of proteomics in biomarker discovery: a primer for the clinician. Physiol Res. 2010; 59(4): 471-497.

(14). Department of Health and Human Services, U.S. Food and Drug Administration. The Critical Path Initiative: Transforming the Way FDA-Regulated Products are Developed, Evaluated, Manu-factured, and Used 2009. Washington DC: fda; 2009.

(15). Goodsaid FM, Frueh FW. Questions and answers about the pilot process for biomarkers qualification at the FDA. Drug Discovery Today: Technologies. 2007; 4(1): 9-11.

(16). Bonassi S, Au WW. Biomarkers in molecular epidemiology stu-dies for health risk prediction. Mutation Research. 2002; 511(1): 73-86.

(17). World Health Organization. Biomarkers and risk assessment: con-cepts and principles Environmental health criteria; N° 155I CPS 1993 [internet]. Geneva: who/ipcs; 1993 [acceso 15 de junio de 2010]. Disponible en: http://www.inchem.org/documents/ehc/ehc/ehc155.htm

(18). Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Foun-tain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 2006; 23(2): 312-328.

(19). Goodsaid FM, Frueh FW, Mattes W. “Strategic paths for biomar-ker qualification”. Toxicology. 2008; 245(3): 219-223.

(20). Schulte P. Opportunities for the development and use of biomar-kers. Toxicol Lett. 1995; 77(1-3): 25-29.

(21). Knudsen LE, Hansen AM. Biomarkers of intermediate endpo-ints in environmental and occupational health. Int J Hyg Environ Health. 2007; 210(3-4): 461-470.

(22). Rodríguez E, García D, Carabias R. Development and validation of a method for the detection and confirmation of biomarkers of exposure in human urine b y means of restricted access material-liquid chromatography–tandem mass spectrometry. Journal of Chromatography A. 2010; 1217(1): 40-48.

(23). Shuker D. The enemy at the gates? DNA adducts as biomarkers of exposure to exogenous and endogenous genotoxic agents. Toxico-logy Letters. 2002; 134: 51-56.

(24). Funk WE, He L, Iavarone AT, Williams ER, Riby J, Rappaport SM. Biochemistry Enrichment of cysteinyl adducts of human serum albumin. Analytical Biochemistry. 2010; 400(1): 61-68.

(25). Richter E, Branner B. Biomonitoring of exposure to aromatic ami-nes: haemoglobinadducts in humans. Journal of Chromatography B. 2002; 778(1-2): 49-62.

(26). Shankar A, Mitchell P, Rochtchina E, Wang J. The association between circulating white blood cell count, triglyceride level and cardiovascular and all cause mortality: population-based cohort study. Atherosclerosis. 2007; 192(1): 177-183.

(27). Maiese K, Chong Z, Hou J, Shang Y. Oxidative stress: Biomar-kers and novel therapeutic pathways. Experimental Gerontology. 2010; 45(3): 217-234.

(28). Lieggi NT, Edvardsson A, O’Brien PJ. Translation of novel anticancer cytotoxicity biomarkers detected with high content analysis from an in vitro predictive model to an in vivo cell model. Veterinary Science Toxicology in Vitro. 2010; 24(8): 2063-2071.

(29). Greystokea A, Hughesa A, Ransona M, Divea C, Cummingsa J, Warda T. Serum biomarkers of apoptosis. European Journal of Cancer Supplements. 2007; 5(5): 115-127.

(30). Whiteaker JR, Zhao L, Zhang HY, Feng L, Piening BD, Ander-son L, et al. Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum bio-markers. AnalyticalBiochemistry. 2007; 362(1): 44-54.

(31). Anderson JE, Hansen LL, Mooren FC, Post M, Hug H, Zuse A, Los M. Methods and biomarkers for the diagnosis and progno-sis of cancer and other diseases: Towards personalized medicine. Drug Resistance. 2006; 9(4-5): 198-210.

(32). Norppa H. Cytogenetic biomarkers and genetic polymorphisms. Toxicology Letters. 2004; 149(1-3): 309-334.

(33). Knudsen LE, Loft SH, Autrup H. Risk assessment: the importan-ce of genetic polymorphisms in man. Mutation Research. 2001; 482(1-2): 83-88.

(34). Timbrell JA. Biomarker in toxicology. Toxicology. 1998; 129(1-7): 1-12.

(35). Gil F. El papel de los biomarcadores en Toxicologíaa humana. Re-vista de Toxicología. 2000; 17(1): 19-26.

(36). Eason C, O’Halloran K. Biomarkers in toxicology versus ecologi-cal risk assessment. Toxicology. 2002; 181-182: 517-521.

(37). Vasseur P, Cossu C. Biomarkers and community indices as com-plementary tools for environmental safety. Environ. Int. 2003; 28(8): 711-717.

(38). Grandjen S, Bonassi S. Linking toxicology to epidemiology: bio-markers and new technologies-special issue overview. Mutat. Res. 2005; 592(1): 3-5.

(39). Bakhtiar R. Biomarkers in drug discovery and development. Jour-nal of Pharmacological and Toxicological Methods. 2008; (57)2: 85-91.

(40). Swenberg JA, Fryar E, Jeong Y, Boysen G, Starr T, Walker VE, Albertini RJ. Biomarkers in Toxicology and Risk Assessment: In-forming Critical Dose-Response Relationships. Chem Res Toxi-col. 2008; 21(1): 253-265.

(41). Moore TJ, Cohen MR, Furger CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch. Intern. Med. 2007; 167(16): 1752-1759.

(42). Mendrick DL. Genomic and genetic biomarkers of toxicity. Toxi-cology. 2008; 245(3): 175-181.

(43). Beals JK. “FDA Releases List of Genomic Biomarkers Predictive of Drug Interactions” [internet]. New York: Medscape Medical News; 2008. [acceso 12 de Julio de 2010]. Disponible en: http://www.medscape.com/viewarticle/578464.

(44). Mateuca R, Lombaert N, Aka P, Decordier I, Kirsch M. Chromo-somal changes: induction, detection methods and applicability in human biomonitoring. Biochimie. 2006; 88(1): 1515-1531.

(45). Smolders R, Bartonova A, Boogaard PJ, Dusinska M, Koppen G, Merlo F, et al. The use of biomarkers for risk assessment: re-porting from the INTARESE/ENVIRISK Workshop in Prague. International journal of hygiene and environmental health. 2010; 213(5): 395-400.

(46). Manno M, Viau C, Cocker J, Colosio C, Lowrye L, Muttif A, Nor-dbergg M, Wangh S. Biomonitoring for occupational health risk assessment (BOHRA). Toxicol Lett. 2010; 192: 3-16.

(47). Shvedova A, Kisin ER, Mercer R, Murray AR, Johnson VJ,Pota-povich A, et al. Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbón nanotubes in mice. Am. J. Phy-siol. Lung. Cell. Mol. 2005; 289(5): L698-708.

(48). Schulte P, Howard J. Genetic Susceptibility and the Setting of Occupational Health Standards. Annu. Rev. Public Health. 2011; 32(1): 149-159.

(49). American Conference of Governmental Industrial Hygienists. Annual Reports of the Committee on TLVs and BEIS for the tear 2009. Cincinnati: acgih; 2010.

(50). German Research Foundation. List of MAK and BAT Values: Maximun Concetrationes and Biological tolerance Values at the Workplace. California: dfg; 2009.

(51). Occupational Safety and Health Administration. Blood lead Labo-ratories Program Descriptions and Background. Salt Lake Techni-cal Center (SLCT). U.S Department of labor, Occupational safety and Health Administration. Washington D.C: osha; 2005.

(52). National Institute for Occupational Safety and Health preventing occupational. nioshList of Antineoplastic and Other Hazardous Drugs in Healthcare settings 2010. Cincinnati: niosh; 2010.

(53). Plant N. Can systems toxicology identify commom biomarker of non-genotoxic carcinogénesis? Toxicology. 2008; 254(3): 164-169.

(54). Vineis P. Use of biomarkers in epidemiology: the example o me-tabolic susceptibility to cancer. Toxicol Lett. 1995; 77(1-3): 163-168.

(55). Kyrtopoulos SA. Biomarkers in environmental carcinogenesis research: Striving for a new momentum. Toxicology Lett. 2006; 162(1): 3-15.

(56). Albertini RJ, Anderson D, Douglas GR, Hagmar L, Hemminki K, Merlo F, et al. IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans. Mutat Res. 2000; 463(1): 111-172.

(57). Fenech M. Biomarkers of genetic damage for cancer epidemiolo-gy. Toxicology. 2002; 181-182: 411-416.

(58). Hick AS, Paczkowski M, Gadano AB, Carballo MA. Biomarca-dores de Genotoxicidad en Individuos Expuestos al Arsénico. Lat. Am. J. Pharm. 2007; 26(5): 691-699.

(59). Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pan-creatic cancer. Mol Cancer Ther. 2006; 5(4): 787-796.

(60). Hsueh YM, Cheng GS, Wu M, Yu HS, Kuo TL, Chen CJ. Multiple risk factors associated with arsenic-induced skin cancer: effects of chronic liver disease and malnutritional status. Br J Cancer. 1995; 71(1): 109-114.

(61). Dopp E, Hartmann L, Florea A, Recklinghausen V, Pieper R, Shokouhi B, et al. Uptake of inorganic and organic derivatives of arsenic associated with induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) cells. Toxicol Appl Pharmacol. 2004; 201(2): 156-165.

(62). Trossero C, Caffarena G, Hure E, Rizzotto M. Detección de Mu-tagenicidad en Compuestos N-Nitrosocon el Test de Ames Acta Farm. Bonaerense.2006; 25(1): 139-144.

(63). Tainsky MA. Genomic and proteomic biomarkers for cancer: a multitude of opportunities. Biochim Biophys Acta 2009 (2):176-193.

(64). Kuramitsu Y, Nakamura K. Proteomic analysis of cancer tissues: shedding light on carcinogenesis and possible biomarkers. Proteo-mics 2006; 6:5650–5661.

(65). Narayan A, Mathur R, Farooque A, Verma A; Dwarakanath B.S Cancer biomarkers - current perspectives. The Indian journal of medical research 2010; 132: 129-149.

Publicado
2012-06-13
Cómo citar
1.
Arango V. SS. Biomarcadores para la evaluación de riesgo en la salud humana. Rev. Fac. Nac. Salud Pública [Internet]. 13 de junio de 2012 [citado 23 de septiembre de 2021];30(1):75-2. Disponible en: https://revistas.udea.edu.co/index.php/fnsp/article/view/9607
Sección
Revisión de tema